^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + tiragolumab (RG6058) (TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Excerpt:
...- Availability of a representative tumor specimen that is suitable for determination of PD-L1 and TIGIT expression...
Trial ID:
Source:
Title:
LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer
Published date:
07/04/2021
Excerpt:
Patients were enrolled from the USA, EU, and Asia. PD-L1 expression was determined…Patients received tiragolumab 400 mg or 600 mg IV every 3 weeks (Q3W) + atezolizumab 1200 mg IV Q3W until disease progression…Tiragolumab combined with atezolizumab was well-tolerated with an acceptable safety profile, and showed preliminary antitumor activity in heavily pretreated patients with metastatic esophageal cancers not previously treated with cancer immunotherapy.
DOI:
https://doi.org/10.1016/j.annonc.2021.06.012
Trial ID:
